Search

Your search keyword '"Tallarico, Valeria"' showing total 8 results
Start Over Author "Tallarico, Valeria"
8 results on '"Tallarico, Valeria"'

1. Effect of SGLT2-Inhibitors on Polygraphic Parameters in Elderly Patients Affected by Heart Failure, Type 2 Diabetes Mellitus, and Sleep Apnea

Author

Armentaro, Giuseppe, primary, Pelaia, Corrado, additional, Condoleo, Valentino, additional, Severini, Giandomenico, additional, Crudo, Giulia, additional, De Marco, Mario, additional, Pastura, Carlo Alberto, additional, Tallarico, Valeria, additional, Pezzella, Rita, additional, Aiello, Domenico, additional, Miceli, Sofia, additional, Maio, Raffaele, additional, Savarese, Gianluigi, additional, Rosano, Giuseppe M. C., additional, and Sciacqua, Angela, additional

Published
2024
Full Text
View/download PDF

2. Cold Anaphylaxis in Children: Italian Case Series and Review of the Literature

Author

Tomei, Leonardo, primary, Saretta, Francesca, additional, Arasi, Stefania, additional, Sarti, Lucrezia, additional, Licari, Amelia, additional, Giovannini, Mattia, additional, Barni, Simona, additional, Liccioli, Giulia, additional, Tallarico, Valeria, additional, Piccorossi, Alessandra, additional, Caffarelli, Carlo, additional, Novembre, Elio, additional, and Mori, Francesca, additional

Published
2023
Full Text
View/download PDF

3. New potential biomarkers for early chronic kidney disease diagnosis in patients with different glucose tolerance status

Author

Cassano, Velia, primary, Pelaia, Corrado, additional, Armentaro, Giuseppe, additional, Miceli, Sofia, additional, Tallarico, Valeria, additional, Perini, Daniele Dallimonti, additional, Fiorentino, Vanessa T., additional, Imbalzano, Egidio, additional, Maio, Raffaele, additional, Succurro, Elena, additional, Hribal, Marta L., additional, Andreozzi, Francesco, additional, Sesti, Giorgio, additional, and Sciacqua, Angela, additional

Published
2023
Full Text
View/download PDF

4. One‐hour post‐load glucose and subclinical left atrial myocardial dysfunction in hypertensive patients

Author

Miceli, Sofia, primary, Cassano, Velia, additional, Clausi, Elvira, additional, Armentaro, Giuseppe, additional, Tallarico, Valeria, additional, Dallimonti Perini, Daniele, additional, Succurro, Elena, additional, Maio, Raffaele, additional, Perticone, Maria, additional, Hribal, Marta L., additional, Montalcini, Tiziana, additional, Andreozzi, Francesco, additional, Sesti, Giorgio, additional, and Sciacqua, Angela, additional

Published
2023
Full Text
View/download PDF

5. KBG syndrome: case report of a novel variant ANKR11 gene mutation and literature review

Author

Sestito Simona, Petrisano Mirella, Crispino Antonio Alessandro, Tallarico Valeria, Pensabene Licia, and Daniela Concolino

Abstract

KBG is a rare genetic disorder that occurs from the ANKRD11 gene mutation. The clinical phenotype of the patients is characterized by dysmorphic features, short stature, intellectual disability and global developmental delay, but may be not present at the first examination. We describe a novel variant ANKRD11 gene mutation.

Published
2022
Full Text
View/download PDF

8. Omalizumab reduces anaphylactic reactions and allows food introduction in food‐allergic in children with severe asthma: An observational study.

Author

Arasi, Stefania, Cafarotti, Arianna, Galletta, Francesca, Panetta, Valentina, Riccardi, Carla, Calandrelli, Veronica, Fierro, Vincenzo, Dahdah, Lamia, Artesani, Maria Cristina, Valluzzi, Rocco Luigi, Pecora, Valentina, Tallarico, Valeria, Dinardo, Giulio, Scalzo, Lucia Lo, and Fiocchi, Alessandro

Subjects
*ASTHMA in children, *FOOD allergy, *ACTIVATION energy, *ANAPHYLAXIS, *OMALIZUMAB
Abstract

Background Objective Methods Results Conclusions Trial Registration Number In Europe, Omalizumab (anti‐IgE) is indicated for the treatment of moderate to severe asthma, but not for IgE‐mediated food allergy (FA).We assessed the impact of Omalizumab on efficacy, safety, and quality of life (FA‐QoL) in patients with moderate to severe asthma and who have a history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat.Food‐allergic children (6–18 years) with moderate to severe asthma underwent oral food challenges (OFCs) to establish the threshold of reaction to the culprit food(s) at baseline (T0) and at 4‐month intervals (T1, T2, and T3) during their first year of treatment with Omalizumab. We recorded the number and severity of food‐allergic reactions, Asthma Control Test (ACT) scores, FA‐QoL, and total IgE levels.In 65 patients allergic to 107 foods, the No Observed Adverse Events Level (NOAEL) at T1 increased: 243‐ and 488‐fold for fresh and baked milk, respectively; 172‐ and 134‐fold for raw and baked egg; 245‐fold for hazelnut; 55‐fold for peanut; 31‐fold for wheat; and 10‐fold for fish. Full tolerance was achieved in 66.4% of OFCs at T1, 58.3% at T2, and 75% at T3. Ninety‐five foods were liberalized in the diet of 55 patients; the remaining 12 were introduced by 10 patients at least in traces. Throughout the study, 40 out of 65 were able to get a free diet. ACT increased from 17 (Q1‐Q3: 15–17) to 23.6 (Q1‐Q3: 23–25). The FA‐QoL score in children ≤12 years decreased from 4.63 ± 0.74 to 2.02 ± 1.13, and in adolescents from 4.68 ± 0.92 to 1.90 ± 1.50.During Omalizumab therapy, a safe reintroduction of allergenic foods is feasible.ClinicalTrials.gov, NCT06316414. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results